Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Evaluating CPX-351 against 7+3 in older newly diagnosed AML

Jeffrey Lancet • 9 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia CPX-351 Cytarabine Daunorubicin

Jeffrey Lancet, MD, of H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, outlines the five-year final results of a Phase III study evaluating CPX-351, a liposomal preparation of cytarabine and daunorubicin at a synergistic ratio, against 7+3 in older, newly diagnosed acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jeffrey Lancet

4:48
Canakinumab with darbepoetin in patients with LR-MDS who are ESA-refractory
Jeffrey Lancet • 8 Dec 2023
5:17
COVALENT-101: investigating menin inhibition with BMF-219 for treating patients with R/R AML or ALL
Jeffrey Lancet • 8 Dec 2023
1:45
The impact of secondary-type mutations in NPM1-mutated AML
Jeffrey Lancet • 11 Dec 2021
6:57
Responses to COVID-19 vaccines in patients with AML and MDS
Jeffrey Lancet • 11 Dec 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals